- Report
- October 2022
- 57 Pages
Global
From €3305EUR$3,500USD£2,813GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,130GBP
- Report
- October 2024
Global
From €3305EUR$3,500USD£2,813GBP
- Report
- November 2021
- 844 Pages
Global
From €4722EUR$5,000USD£4,018GBP
- Report
- April 2023
- 290 Pages
Global
From €3371EUR$3,570USD£2,869GBP
- Book
- July 2023
- 1568 Pages
- Book
- July 2009
- 1116 Pages
Levetiracetam is a medication used to treat epilepsy and other seizure disorders. It is a type of anticonvulsant drug, which works by reducing the abnormal electrical activity in the brain that causes seizures. Levetiracetam is used to treat partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. It is also used to treat Lennox-Gastaut syndrome, a rare form of epilepsy. Levetiracetam is part of the Central Nervous System (CNS) drug market, which includes medications used to treat neurological disorders such as epilepsy, Parkinson's disease, and Alzheimer's disease. The CNS drug market is highly competitive, with many different drugs available to treat the same condition.
Companies in the Levetiracetam market include UCB, Inc., Sun Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., and Teva Pharmaceutical Industries Ltd. Show Less Read more